Next Article in Journal
Burnout Risk and Protection Factors in Certified Nursing Aides
Next Article in Special Issue
Suicide Stigma among Medical Students in Puerto Rico
Previous Article in Journal
Early-Life Air Pollution Exposure, Neighborhood Poverty, and Childhood Asthma in the United States, 1990–2014
Previous Article in Special Issue
Racial Disparities and Preventive Measures to Renal Cell Carcinoma
Open AccessArticle

Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program

1
Division of Cardiovascular Medicine, School of Medicine, University of Puerto Rico Medicine Sciences Campus, P.O. Box 365067, San Juan, PR 00936-5067, USA
2
Department of Biology, Natural Sciences, University of Puerto Rico Rio Piedras Campus, San Juan, PR 00931, USA
3
Pharmaceutical Sciences Department, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA
4
Department of Biology, Natural Sciences, University of Puerto Rico Bayamon Campus, Bayamon, PR 00959, USA
5
Department of Biochemistry, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA
6
Department of Pharmacy Practice, University of Puerto Rico Medical Sciences Campus, San Juan, PR 00936, USA
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2018, 15(6), 1115; https://doi.org/10.3390/ijerph15061115
Received: 5 April 2018 / Revised: 16 May 2018 / Accepted: 28 May 2018 / Published: 30 May 2018
Background: Variations in several clopidogrel-pharmacogenes have been linked to clopidogrel response variability and clinical outcomes. We aimed to determine the frequency distribution of major polymorphisms on CYP2C19, PON1, ABCB1 and P2RY12 pharmacogenes in Puerto Ricans. Methods: This was a cross-sectional, population-based study of 200 unrelated “Guthrie” cards specimens from newborns registered in the Puerto Rican newborn screening program (PRNSP) between 2004 and 2014. Taqman® SNP assay techniques were used for genotyping. Results: Minor allele frequencies (MAF) were 46% for PON1 (rs662), 41% for ABCB1 (rs1045642), 14% for CYP2C19*17, 13% for CYP2C19*2, 12% for P2RY12-H2 and 0.3% for CYP2C19*4. No carriers of the CYP2C19*3 variants were detected. All alleles and genotype proportions were found to be in Hardy–Weinberg equilibrium (HWE). Overall, there were no significant differences between MAFs of these variants in Puerto Ricans and the general population (n = 453) of the 1000 Genome project, except when comparisons to each individual parental group were performed (i.e., Africans, Europeans and East-Asians; p < 0.05). As expected, the prevalence of these markers in Puerto Ricans most resembled those in the 181 subjects from reference populations of the Americas. Conclusions: These prevalence data provide a necessary groundwork for future clinical studies of clopidogrel pharmacogenetics in Caribbean Hispanics. View Full-Text
Keywords: clopidogrel; pharmacogenetics; Puerto Ricans; genotypes; allele frequency clopidogrel; pharmacogenetics; Puerto Ricans; genotypes; allele frequency
Show Figures

Figure 1

MDPI and ACS Style

Hernandez-Suarez, D.F.; Tomassini-Fernandini, J.C.; Cuevas, A.; Rosario-Berrios, A.N.; Nuñez-Medina, H.J.; Padilla-Arroyo, D.; Rivera, N.; Liriano, J.; Vega-Roman, R.K.; Renta, J.Y.; Melin, K.; Duconge, J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int. J. Environ. Res. Public Health 2018, 15, 1115.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop